Zhejiang Taimei Medical Technology (HKG:2576) forecasts its net loss to narrow by 38% to 220 million yuan in 2024 from 356.4 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
The lower loss forecast is attributable to a higher overall gross profit margin and a decline in selling and research and development costs, the filing said.
The medical technology company plans to publish its annual results by the end of March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments